EU/3/19/2145

Table of contents

About

On 26 February 2019, orphan designation (EU/3/19/2145) was granted by the European Commission to Roche Registration GmbH, Germany, for risdiplam for the treatment of spinal muscular atrophy.

Key facts

Active substance
Risdiplam
Disease / condition
Treatment of spinal muscular atrophy
Date of first decision
26/02/2019
Outcome
Positive
EU designation number
EU/3/19/2145

Sponsor's contact details

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
Tel. +49 7624 142892
E-mail: global.eu_regulatory_office@roche.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating